Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL322844 | 1.00 | BTK (0.53) | BTKPIK3CDADORA1GPR119PIK3CA | |
| SCHEMBL18395930 | 0.82 | GPR119 (0.37) | BTKGPR119USP30IRAK4 | |
| SCHEMBL18395928 | 0.82 | GPR119 (0.37) | BTKGPR119USP30IRAK4 | |
| SCHEMBL322835 | 0.80 | PIK3CD (0.57) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL322836 | 0.80 | PIK3CD (0.57) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL15145741 | 0.78 | BTK (0.58) | BTKPIK3CDADORA1GPR119PIK3CA | |
| SCHEMBL322467 | 0.77 | BTK (0.53) | BTKPIK3CDADORA1GPR119PIK3CA | |
| SCHEMBL322468 | 0.77 | BTK (0.53) | BTKPIK3CDADORA1GPR119PIK3CA | |
| SCHEMBL31029604 | 0.77 | KIT (0.49) | GPR119 | |
| SCHEMBL30333389 | 0.77 | KIT (0.49) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2025-02-20 | — | — | US | disclosed |
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2022-08-25 | — | — | US | disclosed |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-20190218217-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218217-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190040061-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| US-20190040061-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| US-20180265509-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2018-09-20 | — | — | US | disclosed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| WO-2013088404-A1 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013088404-A1 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| EP-2590974-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| WO-2013001445-A1 | SOLID FORMS AND SALTS OF TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-01-03 | — | — | WO | disclosed |
| WO-2013001445-A1 | SOLID FORMS AND SALTS OF TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-01-03 | — | — | WO | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012004299-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004299-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040061-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | BTK 150/4885PIK3CD 6/4885ADORA1 543/4885 |
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | BTK 150/4885PIK3CD 6/4885ADORA1 543/4885 |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | BTK 150/4885PIK3CD 6/4885ADORA1 543/4885 |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | BTK 150/4885PIK3CD 6/4885ADORA1 543/4885 |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | BTK 150/4885PIK3CD 6/4885ADORA1 543/4885 |
| US-20190218217-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | PIK3CA, PIK3CD, PIK3CB | BTK 97/4885PIK3CD 2/4885ADORA1 354/4885 |
| US-20180265509-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | BTK 150/4885PIK3CD 6/4885ADORA1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.